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1. Introduction 
Sudden cardiac death (SCD) is among the most common types of mortality in developed 
countries. It for more deaths each year than the total number of deaths from AIDS, breast 
cancer, lung cancer and stroke together. SCD accounts for approximately 50% of all deaths 
from cardiovascular diseases and 20% of total mortality (1). In the general population, SCD 
mostly occurs in individuals who are unrecognized to be at risk (2,3). 
Although the causes of SCD are multiple, the majority (80–85%) of sudden cardiac deaths is 
caused by acute ventricular arrhythmias (4). Traditionally, the risk of ventricular 
arrhythmias has been evaluated based on the duration of QT interval on a standard surface 
ECG. 
2. QT interval 
QT interval is measured in milliseconds (ms) from the Q-top, the beginning of the QRS 
complex, until the end of the T wave and reflects the time between the initial fast 
depolarization of the left ventricle and its subsequent repolarization (5). Duration of the QT 
interval is highly dependent on T wave morphology, which is determined by the differences 
in the time course of repolarization of 3 predominant ventricular myocardial cell types 
(endocardial, epicardial, and M cells) (6). 
The start of the T wave is caused by the more rapid rate of decline of the plateau or phase 2 
of the epicardial action potential, creating a voltage gradient and electrotonic current flow 
across the wall. The gradient gradually increases as the epicardial action potential continues 
to repolarize, reaching a maximum with full repolarization of epicardium; this juncture 
marks the peak of the T wave. Divergence of the plateau of the endocardial AP from that of 
the M cell occurs soon after that of epicardium, causing a voltage gradient between 
endocardium and the M region and thus a current opposite to that generated by the voltage 
gradient that develops between epicardium and the M region. Under normal conditions, 
current flow between the M region and epicardium is greater than that between the M 
region and endocardium, resulting in the inscription of the ascending limb of the upright T 
wave. Once epicardium is fully repolarized, continued repolarization of endocardium leads 
to a progressively larger voltage gradient between endocardium and the M region, giving 
rise to the initial descending limb of the upright T wave. The last cells to repolarize are the 
M cells, contributing to the final segment of the T wave. Full repolarization of the M region 
marks the end of the T wave (7,8). 
www.intechopen.com
 
Advances in Electrocardiograms – Methods and Analysis 
 
142 
In the presence of cardiac disease, ventricular repolarization heterogeneity is increased, 
leading to QT interval prolongation (9). However, QT interval duration is also affected by 
various noncardiac factors, such as age, gender, inflammation, changes in autonomic 
nervous tone, and electrolyte disturbances (10), thereby limiting its use in the analysis of the 
electrophysiological properties of ventricular myocardium. Furthermore, QT interval 
duration is highly dependent on heart rate. Despite a variety of methods that have been 
proposed to derive a rate-corrected (QTc interval), which would allow the comparison of QT 
values obtained at different heart rates, no consensus has been reached so far (11). Since 
there is growing evidence that QT interval prolongation by itself cannot accurately predict 
the pro-arrhythmic potential, other ECG parameters are considered more reliable and have 
been investigated in pre-clinical and clinical studies. 
3. Long QT syndrome 
The long QT syndrome (LQTS) is characterized by the appearance of long QT intervals in 
the electrocardiogram, an atypical polymorphic ventricular tachycardia displaying features 
of torsade de pointes, and a high risk for sudden cardiac death (12). Congenital LQTS can be 
further subdivided into six genotypes distinguished by mutations in at least five different 
ion channel genes located on chromosomes 3, 7, 11, and 21 (13,14). These mutations result in 
defects in the sodium channel (SCN5A, LQT3), the rapidly activating delayed rectifier 
channel (I Kr ) (HERG, LQT2 or KCNE2, LQT6), and the slowly activating delayed rectifier 
channel (I Ks ) (KvLQT1, LQT1 or KCNE1, LQT5), respectively. Acquired LQTS is a term 
long reserved for a syndrome similar to that encountered in the congenital forms but caused 
by exposure to drugs that prolong the duration of the ventricular action potential (15) or to 
QT prolongation secondary to bradycardia, electrolyte imbalance or remodeling of the 
ventricular myocardium that accompanies dilated and hypertrophic cardiomyopathies 
(16,17).  
Management of patients with long QT syndrome is strongly dependent of the genetic basis 
of the disease. The trigger for most of the episodes of life-threatening arrhythmias of long 
QT syndrome is represented by a sudden severe increase in sympathetic activity, which is 
largely mediated through left cardiac sympathetic nerves. (12) Therefore B-adrenergic 
blockade represents the first line of treatment in symptomatic patients with long QT 
syndrome. It has been shown that in LQT1 patients B-blockers significantly reduce life-
threatening events and these patients seldom need more than antiadrenergic therapy. 
Compared to LQT1 patients, LQT2 and LQT 3 patients have more life-threatening events 
despite treatment with B-blockers. (18) In these patients additional therapies are needed. In 
patients who remain symptomatic despite treatment with B-blockers (minority of LQT1 and 
the majority of LQT2 and LQT3 patients) left cardiac sympathetic denervation (LCSD) is to 
be considered. Although moderately invasive (it requires surgical removal of first four 
thoracic ganglia) it has proven effective since it was shown that with LCSD we can achieve 
about 90% reduction in cardiac events and with this a dramatic improvement in patients’ 
quality of life. (19). Regarding ICD therapy it is uniformly agreed that in case of documented 
cardiac arrest ICD should be implanted immediately. However, there are significant 
differences in opinion regarding the use of ICDs in patients without cardiac arrest. It should 
not be forgotten that ICD do not prevent the occurrence of malignant arrhythmias and that 
most of arrhythmias in patients with long QT syndrome are self terminated. Furthermore 
pain associated with shocks can in turn perpetuate malignant rhythm disturbances through 
www.intechopen.com
 
QT Interval and QT Variability 
 
143 
massive catecholamine release. It is therefore of paramount importance to implant only to 
symptomatic patients since there to date no clear benefit of ICDs in asymptomatic patients 
with long QT syndrome has been demonstrated. (20) 
4. Short QT syndrome 
Short QT syndrome (SQTS) is an inheritable primary electrical disease of the heart, 
discovered in 1999. It is characterized by an abnormally short QT interval (<300 ms) and a 
propensity to atrial fibrillation and SCD (21). Like in the case of long QT syndrome there is 
more than one genetic mutation that can lead to a short QT interval in the ECG and so far 
gain-of-function mutations in KCNH2, KCNQ1, KCNJ2, encoding potassium channels and 
loss-of-function mutations in CACNA1C and CACNB2b, encoding L-type calcium channel 
subunits have been identified (22). Shortening of the effective refractory period combined 
with increased dispersion of repolarization is the likely substrate for re-entry and life 
threatening tachyarrhythmias (23). ICD is the therapy of choice in patients with a short QT 
syndrome. However, antiarrhythmic drug therapy may constitute a potential adjunct or 
even an alternative therapy in children and newborns, where ICD implantation is very 
challenging. To date several antiarrhythmic agents were tested in this patient population. 
Flecainide, sotalol and ibutilide (acting through blocking of the rapidly activating delayed 
rectifier potassium current) all failed to prolong the QT interval in patients with short QT 
syndrome.(24) In vitro electrophysiological studies showed that the mutation of the IKr 
channel led to a reduced ability of these antiarrhythmic agents to block the channel.(25) It 
was recently shown that quinidine, in contrast to flecainide, ibutilide and sotalol, can 
normalise the QT interval at resting heart rates. Additionally, quinidine also restored the 
heart rate dependence of QT interval towards an adaptation range of normal subjects.(26) 
Although studied extensively, the exact mechanism of its action for now remains 
incompletely understood. We have to keep in mind, however, that short QT interval can be 
a consequence of several gain- and loss-of-function mutations. Therefore for this patient 
population a uniform medical management currently cannot be recommended. 
5. QT variability 
Repolarization of the ventricular myocardium is a complex process that varies in duration 
from site to site and from beat to beat. The mechanisms that govern spatial heterogeneity in 
ventricular repolarization are well studied, and are largely related to variation in ion 
channel function and density from one myocardial region to another (27). Ventricular wall 
comprises of 3 cell types: epicardial, M and endocardial cells. Epicardial and M cell action 
potentials differ from endocardial cells with respect to the morphology of phase 1. These 
cells possess a prominent transient outward current mediated notch responsible for the 
'spike and dome' morphology of the epicardial and M cell response. M cells are 
distinguished from the other cell types in that they display a smaller slowly activating 
delayed rectifier current, but a larger late sodium current and sodium-calcium exchange 
current. Because of these differences spatial heterogeneity in ventricular repolarization 
occurs.  
The mechanisms responsible for temporal fluctuations in repolarization, however, are 
poorly understood. Several clinical studies over the past decade have examined beat-to-beat 
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variability in QT interval of the surface electrocardiogram (ECG) as a means for quantifying 
temporal repolarization lability (28).  
Recently, a PC-based electrocardiogram software program has been developed that in real 
time, acquires, analyzes, and displays QT variability in each of the 8 independent channels 
that constitute the 12-lead conventional electrocardiogram (29). The system also analyzes 
and displays the QT variability from QT-interval signals that are derived from multiple 
channels and from singular value decomposition such that the effect of noise and other 
artifacts on the QTV results are substantially reduced compared with existing single-channel 
methods. 
When analysis begins, templates for the overall ECG signal in each channel are first formed. 
To construct the initial templates, the first 20 beats are collected into a single averaging bin. 
Then, the mode of the probability function of the R-R interval is created for those beats and 
its maximum determined. Finally, those 10 beats that are closest to the determined 
maximum are selected, and a template ECG wave for the same beats is then obtained by 
averaging the superimposed ECG signals based on the fiducial point of the QRS wave. 
After the initial global templates have been constructed, breaking points called PQbreak 
(between the P wave and the QRS complex), QTbreak (between the QRS complex and the T 
wave), Tend (the final point of the T wave), and Pini (the initial point of the P wave) are 
used to construct individual templates for the 3 principal waveforms QRS, T, and P.  
The principal steps of the algorithm used in analyzing QT variability are described in detail, 
as follows: 
1. The template beat φ(n), where n is the sample number, is constructed from the selected 
beats using a signal averaging technique. Only those beats with shape similar to the 
template are selected for averaging. Because the program automatically determines the 
borders of each wave component (P, QRS, and T templates, as described previously) 
and therefore the time window for matching of waves, its remaining task is to shift the 
particular incoming wave component with respect to the template until obtaining an 
acceptable match. The matching algorithm is based on the least square deviation of the 
incoming wave vs the template. 
2. The matching of waves is performed in 2 substeps. First, a broader time interval 
containing the complete wave component is used to reach the best fit. Second, each 
wave of any incoming beat is shifted to or from the trigger point to achieve the best 
alignment with the template in the appropriate time window. For this purpose, an error 
function of time shifting is defined as the sum of the squared differences between the 
template wave (P, QRS, or T) and the appropriate shifted version of the incoming beat. 
3. The program uses the QT variability algorithm to generate, in real time, the time series 
of the QT interval along with that of the R-R interval. Time series are analyzed 
according to the recommendations of the Task Force of the European Society of 
Cardiology and the North American Society of Pacing and Clinical Electrophysiology 
(30) using specific indices such as the SD of normal-to-normal (NN) R-R and QT 
intervals (SDNN R-R and SDNN QT, respectively), the root mean square (RMS) of the 
successive interval difference (RMSSD R-R and RMSSD QT), and so on.  
6. Clinical application 
Although QT interval prolongation has been proposed as a risk factor for death in an 
apparently healthy population in patients after myocardial infarction in diabetic patients, 
www.intechopen.com
 
QT Interval and QT Variability 
 
145 
and patients with advanced heart failure, its direct relation to pro-arrhythmic risk remains 
questionable (1,17). 
While measuring subtle variation in QT interval duration is technically challenging, new 
methodology (28,29) has enabled investigators to study the effect of disease states on 
ventricular repolarization variability, and the prognostic value of the QT interval variability 
measurement. QT variability has been shown to be elevated in congestive heart failure 
(CHF) (28), ischemia (31), and some types of hypertrophic cardiomyopathy (26). Increased 
QT variability was also found to predict appropriate implantable cardioverter-defibrillator 
shocks in the MADIT-II (Multicenter Automatic Defibrillator Implantation Trial-II) study 
(33), as well as total mortality and sudden death in post-myocardial infarction patients 
without implantable cardioverter-defibrillators (34). 
Based on the current clinical evidence it appears that although currently considered ‘the 
golden standard’ QT interval measurement will in the future be replaced by novel, more 
reproducible automated methods that will allow for better prediction of arrhythmic events 
in various clinical settings. 
7. Pharmaceutical application 
Pro-arrhythmic drug effects have been one of the most common reasons for withdrawal of 
drugs from the market in many therapeutic areas. Currently, the potential pro-arrrhytmic 
effects of drugs are addressed in accordance with The ‘International Conference on 
Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human 
Use’ (ICH) E14 clinical guidance issued in May 2005. The centre-piece of the guidance is the 
‘thorough QT/QTc study’ (TQT), which is a dedicated study with the primary objective to 
quantify the effect of a new molecular entity on the QT interval (35).  
Although considered the ‘golden standard’, use of QT interval duration as a surrogate 
marker for the prediction of drug-induced arrhythmias has several pitfalls (36,37): 
- Many drugs affect both QT interval duration and heart rate. Since all current heart rate 
correction methods are imperfect, it is difficult to distinguish the drug-related changes 
in QT interval from those caused by heart rate alterations. 
- Since QT interval duration is dependent on several non-cardiac factors (e.g. 
inflammation, autonomic nervous system), the therapeutic effect of drugs on the 
underlying disease may mask the potential adverse drug effects on cardiac 
repolarization and QT interval. 
- QT interval is used as a surrogate marker of arrhythmias; however, its relationship to 
the arrhythmic events has been seriously questioned in the recent clinical studies. 
- It is assumed, but has not been proved, that even a small drug-induced increase in QT 
interval indicates some risk of arrhythmias. 
Given these limitations it is clear that in order to adequately address pro-arrhythmic risk of 
drugs it is necessary to look beyond the drug-induced changes of QT interval. Other drug-
induced ECG changes, associated pro-arrhythmic risks, and threshold of magnitude of 
changes should be considered as a cause for concern. Therefore, novel advanced ECG 
technologies should be develop do better define drug-induced arrhythmogenesis. 
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